Alzheimer’s Therapy Elenbecestat Reduces Brain Amyloid Levels, is Safe and Well-Tolerated, Trial Shows

Alzheimer’s Therapy Elenbecestat Reduces Brain Amyloid Levels, is Safe and Well-Tolerated, Trial Shows
Treatment with the investigational compound elenbecestat reduced brain amyloid beta levels and was safe and well-tolerated, according to Phase 2 clinical trial results. The presence of amyloid beta plaques is a major characteristic of the brains of Alzheimer’s disease patients. Amyloid beta is produced through the work of a key enzyme called BACE (beta-amyloid cleaving enzyme). Elenbecestat is an oral inhibitor of BACE being developed by by Eisai and
Subscribe or to access all post and page content.